 |
 Video: What is a Stock Split?
|
|
|
| Vincerx Pharma is a clinical-stage biopharmaceutical company focused on utilizing its development and oncology capabilities to develop therapies intended to address unmet medical needs for the treatment of cancer. Co.'s pipeline consists of enitociclib and a proprietary modular bioconjugation platform, which includes a small molecule drug-conjugate, VIP236 and preclinical antibody drug-conjugates, VIP943 and VIP924. Co. had been granted an exclusive, royalty-bearing, worldwide license under certain Bayer AG patents and know-how to develop, use, manufacture, commercialize, sublicense, and distribute multiple clinical and preclinical stage compounds. According to our Vincerx Pharma stock split history records, Vincerx Pharma has had 0 splits. | |
|
Vincerx Pharma (VINC) has 0 splits in our Vincerx Pharma stock split history database.
Looking at the Vincerx Pharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Vincerx Pharma shares, starting with a $10,000 purchase of VINC, presented on a split-history-adjusted basis factoring in the complete Vincerx Pharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/28/2020 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$9.35 |
|
| End price/share: |
$0.90 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-90.41% |
|
| Average Annual Total Return: |
-45.07% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$959.51 |
|
| Years: |
3.91 |
|
|
|
|
|
